MYDA Advisors LLC bought a new position in Beigene Ltd (NASDAQ:BGNE) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 4,600 shares of the company’s stock, valued at approximately $450,000.
Other institutional investors have also recently modified their holdings of the company. Employees Retirement System of Texas bought a new position in shares of Beigene in the 4th quarter valued at about $3,909,000. Alps Advisors Inc. lifted its holdings in shares of Beigene by 15.9% in the 3rd quarter. Alps Advisors Inc. now owns 41,739 shares of the company’s stock valued at $4,318,000 after acquiring an additional 5,732 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Beigene by 25.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 13,496 shares of the company’s stock valued at $607,000 after acquiring an additional 2,700 shares during the last quarter. Belpointe Asset Management LLC bought a new position in shares of Beigene in the 3rd quarter valued at about $1,642,000. Finally, Westpac Banking Corp bought a new position in shares of Beigene in the 3rd quarter valued at about $662,000. 52.22% of the stock is owned by institutional investors.
BGNE has been the subject of a number of analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price target (up previously from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Cowen reaffirmed a “buy” rating on shares of Beigene in a report on Tuesday, November 14th. Maxim Group set a $120.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research report on Tuesday, November 14th. ValuEngine lowered shares of Beigene from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Beigene presently has an average rating of “Buy” and an average target price of $127.67.
Beigene Ltd (NASDAQ BGNE) traded down $2.30 during trading hours on Wednesday, hitting $153.18. 367,928 shares of the stock traded hands, compared to its average volume of 364,607. Beigene Ltd has a 1-year low of $34.36 and a 1-year high of $164.15. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $8,265.08, a P/E ratio of -63.72 and a beta of 0.58.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($2.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.40). The firm had revenue of $18.17 million for the quarter, compared to analyst estimates of $23.00 million. research analysts forecast that Beigene Ltd will post -7.69 earnings per share for the current fiscal year.
In other Beigene news, CEO John Oyler sold 20,137 shares of Beigene stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $96.46, for a total value of $1,942,415.02. Following the completion of the transaction, the chief executive officer now owns 110,179 shares of the company’s stock, valued at $10,627,866.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was purchased at an average cost of $101.00 per share, with a total value of $199,999,998.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 164,475 shares of company stock valued at $22,963,626. 19.90% of the stock is currently owned by corporate insiders.
WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://ledgergazette.com/2018/03/14/myda-advisors-llc-takes-450000-position-in-beigene-ltd-bgne.html.
Beigene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.